Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × HLX07 × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Other solid neoplasm 1

Conditions

Interventions

Cisplatin 67 Paclitaxel 65 Carboplatin 60 pembrolizumab 56 Irinotecan 54 Gemcitabine 52 Injections 43 Docetaxel 42 Cyclophosphamide 34 Pemetrexed 31 Fluorouracil 31 Oxaliplatin 28 Capecitabine 28 Bevacizumab 28 Leucovorin 24 Nivolumab 21 tislelizumab 19 atezolizumab 19 Etoposide 17 Temozolomide 16 Cetuximab 16 Bortezomib 15 durvalumab 14 Topotecan 14 Sorafenib 14 Erlotinib Hydrochloride 14 olaparib 13 fludarabine 13 alvocidib 13 Taxes 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05360368 2022-05-05

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Shanghai Henlius Biotech

Phase 1 Unknown

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡